巯甲丙脯氨酸(Capfopril, SQ 14225,简称巯甲)是1977年合成的一种新的口服血管紧张素转换酶(ACE)抑制剂。1970年国内合成此药并应用于临床。近年来应用日益广泛 现介绍如下。 一、难治性心力衰竭 心力衰竭时,心排血量减少,肾素-血管紧张素-醛固酮(R-A-A)系统活性增加。血管紧张素Ⅱ(ATⅡ)可使周围血管阻力增加,醛固酮(ALD)则可加重钠水潴留,R-A-A系统激活可导致心脏前后负荷加重,从而形成恶性循环。巯甲通过对血管紧张素Ⅰ(ATⅠ)转换酶的抑制,可阻断R-A-A系统,使AT Capfopril (SQ 14225, abbreviated as capsaicinoid) is a new oral angiotensin converting enzyme (ACE) inhibitor synthesized in 1977. In 1970 the domestic synthesis of the drug and applied to clinical. In recent years, the increasingly wide range of applications are described below. First, refractory heart failure, cardiac output decreased, renin - angiotensin - aldosterone (R-A-A) system activity increased. Angiotensin Ⅱ (AT Ⅱ) can increase peripheral vascular resistance, aldosterone (ALD) can increase sodium and water retention, R-A-A system activation can lead to increased cardiac load before and after, resulting in a vicious circle. Captopril through the angiotensin Ⅰ (AT Ⅰ) converting enzyme inhibition can block the R-A-A system, AT